Extrait

The primary objective of the trial is to evaluate the response to pembrolizumab monotherapy in cohorts of patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, PCNSL, rare thyroid cancer, rare malignant neuroendocrine cancer or germ-cell cancer, which is resistant or refractory to standard therapy, and for which no other treatment options are available.

Critère d'inclusion

• Patients with unresectable locally advanced or metastatic, rare soft tissue sarcoma, visceral sarcoma, or bone sarcoma, rare ovarian cancer, primary central nervous system lymphomas (PCNSL), rare thyroid cancer, rare malignant neuroendocrine cancer or germ-cell cancer, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available

Liens

• euctr